BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 608539)

  • 1. In vitro and in vivo effects of Corynebacterium parvum on lymphocyte transformation.
    Fisher RA
    Dev Biol Stand; 1977 Apr 13-15; 38():461-6. PubMed ID: 608539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of intravenous infusion of Corynebacterium parvum on an immune profile of women with breast cancer.
    Webster DJ; Chare MJ; Baum M
    Dev Biol Stand; 1977 Apr 13-15; 38():467-70. PubMed ID: 608540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-specific inhibitory processes of immunological and mitogenic cellular responses.
    Liacopoulos M; Lambert F; Liacopoulos P
    Immunology; 1980 Sep; 41(1):143-52. PubMed ID: 6448806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitogenicity of Corynebacterium parvum for mouse lymphocytes.
    Zola H
    Clin Exp Immunol; 1975 Dec; 22(3):514-21. PubMed ID: 817854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of Corynebacterium parvum on the humoral and cellular immune systems in patients with breast cancer.
    Minton JP; Rossio JL; Dixon B; Dodd MC
    Clin Exp Immunol; 1976 Jun; 24(3):441-7. PubMed ID: 1084821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-tumour C. parvum therapy in gastric carcinoma; a pilot study.
    Dykes PW; Trejdosiewicz LK
    Dev Biol Stand; 1977 Apr 13-15; 38():547-52. PubMed ID: 608548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum.
    Lichtenstein A; Berek J; Bast R; Spina C; Hacker N; Knapp RC; Zighelboim J
    J Biol Response Mod; 1984 Aug; 3(4):371-8. PubMed ID: 6541243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial with Corynebacterium parvum.
    Medenica R; Girard JP; Maurice P
    Dev Biol Stand; 1977 Apr 13-15; 38():483-5. PubMed ID: 344103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon production and lymphocyte stimulation in human leucocyte cultures stimulated by Corynebacterium parvum.
    Hirt HM; Schwenteck M; Becker H; Kirchner H
    Clin Exp Immunol; 1978 Jun; 32(3):471-6. PubMed ID: 688696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients.
    Thatcher N; Crowther D
    Dev Biol Stand; 1977 Apr 13-15; 38():449-53. PubMed ID: 608536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological response in patients receiving Corynebacterium parvum therapy.
    Osborn DE; Castro JE
    Clin Oncol; 1977 Jun; 3(2):155-64. PubMed ID: 872468
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical experience in the use of C. parvum in the treatment of locally advanced carcinoma of the breast.
    Chare MJ; Webster DJ; Baum M
    Dev Biol Stand; 1977 Apr 13-15; 38():495-9. PubMed ID: 344104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical studies with Corynebacterium parvum.
    Mitcheson HD; Castro JE
    Dev Biol Stand; 1977 Apr 13-15; 38():509-14. PubMed ID: 344105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of sodium diethyldithiocarbamate, Corynebacterium parvum and mycobacterium cell wall extract on in vitro blastogenic responses of bovine blood lymphocytes.
    Archambault D; Morin G; Elazhary MA
    Cornell Vet; 1989 Jan; 79(1):11-24. PubMed ID: 2536308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of a multi-modal schedule with Corynebacterium parvum.
    McIntosh IH; Thynne GS; Bejrajati P; Walsh G; Greening WP
    Dev Biol Stand; 1977 Apr 13-15; 38():477-82. PubMed ID: 344102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of thermal response of normal and malignant tissues by Corynebacterium parvum.
    Urano M; Yamashita T; Suit HD; Gerweck LE
    Cancer Res; 1984 Jun; 44(6):2341-7. PubMed ID: 6722772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local Corynebacterium parvum therapy in early breast cancer: a pilot study.
    Boak JL
    Clin Oncol; 1978 Sep; 4(3):235-42. PubMed ID: 750126
    [No Abstract]   [Full Text] [Related]  

  • 18. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity.
    Shu SY; Chou T; Sakai K
    J Immunol; 1989 Jul; 143(2):740-8. PubMed ID: 2738408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A survey of patients' reactions to intravenous Corynebacterium parvum therapy.
    Palmer BV; Walsh G; Smedley P; McIntosh IH; Greening WP
    Dev Biol Stand; 1977 Apr 13-15; 38():529-33. PubMed ID: 608547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accessory cell function in tumor-bearing mice and effects of Corynebacterium parvum.
    Okuda S; Taniguchi K; Kubo C; Nomoto K
    J Natl Cancer Inst; 1982 Dec; 69(6):1293-7. PubMed ID: 6292563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.